Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation : A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)
A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of Rezafungin for injection versus the standard antimicrobial regimen for the prevention of invasive fungal diseases in subjects undergoing allogeneic blood and marrow transplantation..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
ClinicalTrials.gov - (2024) vom: 25. März Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 30, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 03, 2024, Last updated: April 03, 2024 |
---|
Study ID: |
NCT04368559 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG000036315 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG000036315 | ||
003 | DE-627 | ||
005 | 20240403010513.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240313s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG000036315 | ||
035 | |a (UBBS_Klinische_Studien)NCT04368559 | ||
035 | |a (UBBS_Klinische_Studien)CD101.IV.3.08 | ||
035 | |a (UBBS_Klinische_Studien)2017-004981-85 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation |b A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 30, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 03, 2024, Last updated: April 03, 2024 | ||
520 | |a A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of Rezafungin for injection versus the standard antimicrobial regimen for the prevention of invasive fungal diseases in subjects undergoing allogeneic blood and marrow transplantation. | ||
650 | 2 | |a Infections | |
650 | 2 | |a Communicable Diseases | |
650 | 2 | |a Mycoses | |
650 | 2 | |a Candidiasis | |
650 | 2 | |a Pneumonia, Pneumocystis | |
650 | 2 | |a Invasive Fungal Infections | |
650 | 2 | |a Candidemia | |
650 | 2 | |a Candidiasis, Invasive | |
650 | 2 | |a Fungemia | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Recruiting | |
650 | 4 | |a Phase: Phase 3 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 25. März |
773 | 1 | 8 | |g year:2024 |g day:25 |g month:03 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04368559 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2024 |b 25 |c 03 |